Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Jennifer A, Huntington"'
Autor:
Ignacio Martin-Loeches, Andrew F. Shorr, Richard G. Wunderink, Marin H. Kollef, Jean-François Timsit, Brian Yu, Jennifer A. Huntington, Erin Jensen, Christopher J. Bruno
Publikováno v:
Annals of Intensive Care, Vol 13, Iss 1, Pp 1-13 (2023)
Abstract Background The pivotal ASPECT-NP trial showed ceftolozane/tazobactam was non-inferior to meropenem for the treatment of ventilated hospital-acquired/ventilator-associated bacterial pneumonia (vHABP/VABP). Here, we evaluated treatment outcome
Externí odkaz:
https://doaj.org/article/adee689dce844e799cdeabcd4c0e34b1
Autor:
Emmanuel Roilides, John S. Bradley, Julia Lonchar, Jennifer A. Huntington, Prachi Wickremasingha, Feng-Hsiu Su, Christopher J. Bruno, Matthew G. Johnson
Publikováno v:
Microbiology Spectrum, Vol 11, Iss 5 (2023)
ABSTRACT Ceftolozane/tazobactam is approved for the treatment of patients from birth to
Externí odkaz:
https://doaj.org/article/46e4bb8e3e354f6087e7fa2f5eb88afd
Autor:
Marin H. Kollef, Jean-François Timsit, Ignacio Martin-Loeches, Richard G. Wunderink, Jennifer A. Huntington, Erin H. Jensen, Brian Yu, Christopher J. Bruno
Publikováno v:
Critical Care, Vol 26, Iss 1, Pp 1-13 (2022)
Abstract Background Ceftolozane/tazobactam, a combination antibacterial agent comprising an anti-pseudomonal cephalosporin and β-lactamase inhibitor, is approved for the treatment of hospital-acquired/ventilator-associated bacterial pneumonia (HABP/
Externí odkaz:
https://doaj.org/article/c38430b8642f45b995171dd794db572c
Autor:
Yihong Sun, Jia Fan, Gang Chen, Xiaofei Chen, Xiaoling Du, Ye Wang, Hui Wang, Fang Sun, Matthew G. Johnson, Mekki Bensaci, Jennifer A. Huntington, Christopher J. Bruno
Publikováno v:
International Journal of Infectious Diseases, Vol 123, Iss , Pp 157-165 (2022)
ABSTRACT: Objectives: This study aimed to evaluate the efficacy and safety of ceftolozane/tazobactam (C/T) plus metronidazole versus meropenem plus placebo for the treatment of complicated intra-abdominal infection (cIAI) in Chinese adult participant
Externí odkaz:
https://doaj.org/article/fb4b746d90b44c5d87424025a074ad80
Autor:
Andrew F. Shorr, Christopher J. Bruno, Zufei Zhang, Erin Jensen, Wei Gao, Hwa-Ping Feng, Jennifer A. Huntington, Brian Yu, Elizabeth G. Rhee, Carisa De Anda, Sumit Basu, Marin H. Kollef
Publikováno v:
Critical Care, Vol 25, Iss 1, Pp 1-12 (2021)
Abstract Background The randomized, double-blind, phase 3 ASPECT-NP trial evaluated the efficacy of 3 g of ceftolozane/tazobactam (C/T) versus 1 g of meropenem infused every 8 h for 8 to 14 days for treatment of adults with hospital-acquired bacteria
Externí odkaz:
https://doaj.org/article/3b53978e253247d8b28a3333ab805866
Autor:
Jean-François Timsit, Jennifer A. Huntington, Richard G. Wunderink, Nobuaki Shime, Marin H. Kollef, Ülo Kivistik, Martin Nováček, Álvaro Réa-Neto, Ignacio Martin-Loeches, Brian Yu, Erin H. Jensen, Joan R. Butterton, Dominik J. Wolf, Elizabeth G. Rhee, Christopher J. Bruno
Publikováno v:
Critical Care, Vol 25, Iss 1, Pp 1-14 (2021)
Abstract Background Ceftolozane/tazobactam is approved for treatment of hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) at double the dose approved for other infection sites. Among nosocomial pneumonia subtypes, ventilated HAB
Externí odkaz:
https://doaj.org/article/b8ee6048ea624162b18dfef8acdeaed8
Autor:
Emmanuel Roilides, Negar Ashouri, John S. Bradley, Matthew G. Johnson, Julia Lonchar, Feng-Hsiu Su, Jennifer A. Huntington, Myra W. Popejoy, Mekki Bensaci, Carisa De Anda, Elizabeth G. Rhee, Christopher J. Bruno
Publikováno v:
Pediatric Infectious Disease Journal. 42:292-298
Publikováno v:
BMC Infectious Diseases, Vol 17, Iss 1, Pp 1-8 (2017)
Abstract Background Diabetes mellitus and hyperglycemia are associated with increased susceptibility to bacterial infections and poor treatment outcomes. This post hoc evaluation of the treatment of complicated intra-abdominal infections (cIAI) and c
Externí odkaz:
https://doaj.org/article/fa97e14e838e4cc8a1c0700dcd409c51
Autor:
Ignacio, Martin-Loeches, Jean-François, Timsit, Marin H, Kollef, Richard G, Wunderink, Nobuaki, Shime, Martin, Nováček, Ülo, Kivistik, Álvaro, Réa-Neto, Christopher J, Bruno, Jennifer A, Huntington, Gina, Lin, Erin H, Jensen, Mary, Motyl, Brian, Yu, Davis, Gates, Joan R, Butterton, Elizabeth G, Rhee
Publikováno v:
J Antimicrob Chemother
Objectives In the ASPECT-NP trial, ceftolozane/tazobactam was non-inferior to meropenem for treating nosocomial pneumonia; efficacy outcomes by causative pathogen were to be evaluated. Methods Mechanically ventilated participants with hospital-acquir
Autor:
Carisa De Anda, Christopher Bruno, Hwa Ping Feng, Sumit Basu, Brian Yu, Elizabeth G. Rhee, Erin Jensen, Jennifer A. Huntington, Andrew F. Shorr, Marin H. Kollef, Wei Gao, Zufei Zhang
Publikováno v:
Critical Care, Vol 25, Iss 1, Pp 1-12 (2021)
Critical Care
Critical Care
Background The randomized, double-blind, phase 3 ASPECT-NP trial evaluated the efficacy of 3 g of ceftolozane/tazobactam (C/T) versus 1 g of meropenem infused every 8 h for 8 to 14 days for treatment of adults with hospital-acquired bacterial pneumon